Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model

British Journal of Haematology

Volumn 170, Issue 4, 2015, Pages 515-522

  Gassner, Franz J ^a,b   Zaborsky, Nadja ^a,b   Catakovic, Kemal ^a,b   Rebhandl, Stefan ^a,b   Huemer, Michael ^a,b   Egle, Alexander ^a,b   Hartmann, Tanja N ^a,b   Greil, Richard ^a,b   Geisberger, Roland ^a,b  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b Salzburg Cancer Research Institute   (Austria)

Author keywords

Chemoimmunotherapy; Chronic lymphocytic leukaemia; PDCD1; T cell exhaustion; Tumour surveillance

Indexed keywords

LYMPHOCYTE ACTIVATION GENE 3; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; LYMPH NODE; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PURIFICATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE EXHAUSTION; TRANSGENE; TUMOR CELL DESTRUCTION; UPREGULATION; ANIMAL; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; GENE EXPRESSION REGULATION, LEUKEMIC; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84937799737     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13467     Document Type: Article

References (40)

1. Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., Schuster, S.J., Millenson, M.M., Cattry, D., Freeman, G.J., Rodig, S.J., Chapuy, B., Ligon, A.H., Zhu, L., Grosso, J.F., Kim, S.Y., Timmerman, J.M., Shipp, M.A. & Armand, P. (2015) PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin's lymphoma. The New England Journal of Medicine, 372, 311-319.
2. Baitsch, L., Fuertes-Marraco, S.A., Legat, A., Meyer, C. & Speiser, D.E. (2012) The three main stumbling blocks for anticancer T cells. Trends in Immunology, 33, 364-372.
3. Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H., Freeman, G.J. & Ahmed, R. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 439, 682-687.
4. Bichi, R., Shinton, S.A., Martin, E.S., Koval, A., Calin, G.A., Cesari, R., Russo, G., Hardy, R.R. & Croce, C.M. (2002) Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proceedings of the National Academy of Sciences of the United States of America, 99, 6955-6960.
5. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nature Immunology, 10, 29-37.
6. Brahmer, J.R., Tykodi, S.S., Chow, L.Q.M., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., Pitot, H.C., Hamid, O., Bhatia, S., Martins, R., Eaton, K., Chen, S.M., Salay, T.M., Alaparthy, S., Grosso, J.F., Korman, A.J., Parker, S.M., Agrawal, S., Goldberg, S.M., Pardoll, D.M., Gupta, A. & Wigginton, J.M. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New England Journal of Medicine, 366, 2455-2465.
7. Brusa, D., Serra, S., Coscia, M., Rossi, D., D'Arena, G., Laurenti, L., Jaksic, O., Fedele, G., Inghirami, G., Gaidano, G., Malavasi, F. & Deaglio, S. (2013) The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica, 98, 953-963.
8. Curiel, T.J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K.L., Daniel, B., Zimmermann, M.C., David, O., Burow, M., Gordon, A., Dhurandhar, N., Myers, L., Berggren, R., Hemminki, A., Alvarez, R.D., Emilie, D., Curiel, D.T., Chen, L. & Zou, W. (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Medicine, 9, 562-567.
9. Frydecka, I., Kosmaczewska, A., Bocko, D., Ciszak, L., Wolowiec, D., Kuliczkowski, K. & Kochanowska, I. (2004) Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia. British Journal of Cancer, 90, 2042-2048.
10. Gassner, F.J., Weiss, L., Geisberger, R., Hofbauer, J.P., Egle, A., Hartmann, T.N., Greil, R. & Tinhofer, I. (2011) Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. Cancer Immunology, Immunotherapy, 60, 75-85.
11. Gassner, F.J., Zaborsky, N., Neureiter, D., Huemer, M., Melchardt, T., Egle, A., Rebhandl, S., Catakovic, K., Hartmann, T.N., Greil, R. & Geisberger, R. (2014) Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. Haematologica, 99, 67-69.
12. Goddard, R.V., Prentice, A.G., Copplestone, J.A. & Kaminski, E.R. (2001) Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate. Clinical and Experimental Immunology, 126, 16-28.
13. Gorgun, G., Ramsay, A.G., Holderried, T.A., Zahrieh, D., Le Dieu, R., Liu, F., Quackenbush, J., Croce, C.M. & Gribben, J.G. (2009) E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 106, 6250-6255.
14. Hamblin, A.D. & Hamblin, T.J. (2008) The immunodeficiency of chronic lymphocytic leukaemia. British Medical Bulletin, 87, 49-62.
15. Hofbauer, J.P., Heyder, C., Denk, U., Kocher, T., Holler, C., Trapin, D., Asslaber, D., Tinhofer, I., Greil, R. & Egle, A. (2011) Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia, 25, 1452-1458.
16. Holler, C., Pinon, J.D., Denk, U., Heyder, C., Hofbauer, S., Greil, R. & Egle, A. (2009) PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood, 113, 2791-2794.
17. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T. & Minato, N. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proceedings of the National Academy of Sciences of the United States of America, 99, 12293-12297.
18. Johnson, A.J., Lucas, D.M., Muthusamy, N., Smith, L.L., Edwards, R.B., De Lay, M.D., Croce, C.M., Grever, M.R. & Byrd, J.C. (2006) Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood, 108, 1334-1338.
19. Kirchberger, S., Majdic, O., Steinberger, P., Bluml, S., Pfistershammer, K., Zlabinger, G., Deszcz, L., Kuechler, E., Knapp, W. & Stockl, J. (2005) Human rhinoviruses inhibit the accessory function of dendritic cells by inducing sialoadhesin and B7-H1 expression. The Journal of Immunology, 175, 1145-1152.
20. Mackus, W.J., Frakking, F.N., Grummels, A., Gamadia, L.E., De Bree, G.J., Hamann, D., Van Lier, R.A. & Van Oers, M.H. (2003) Expansion of CMV-specific CD8 + CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia. Blood, 102, 1057-1063.
21. Mkrtichyan, M., Najjar, Y.G., Raulfs, E.C., Abdalla, M.Y., Samara, R., Rotem-Yehudar, R., Cook, L. & Khleif, S.N. (2011) Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. European Journal of Immunology, 41, 2977-2986.
22. Momtaz, P. & Postow, M.A. (2014) Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Journal of Pharmacogenomics and Personalized Medicine, 7, 357-365.
23. Nishimura, H., Minato, N., Nakano, T. & Honjo, T. (1998) Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. International Immunology, 10, 1563-1572.
24. Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity, 11, 141-151.
25. Nunes, C.T., Wong, R., Mason, M., Fegan, C., Man, S. & Pepper, C. (2012) Expansion of a CD8 + PD-1 + replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clinical Cancer Research, 18, 678-687.
26. Patten, P.E., Buggins, A.G., Richards, J., Wotherspoon, A., Salisbury, J., Mufti, G.J., Hamblin, T.J. & Devereux, S. (2008) CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood, 111, 5173-5181.
27. Plander, M., Seegers, S., Ugocsai, P., Diermeier-Daucher, S., Ivanyi, J., Schmitz, G., Hofstadter, F., Schwarz, S., Orso, E., Knuchel, R. & Brockhoff, G. (2009) Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia, 23, 2118-2128.
28. Pleyer, L., Egle, A., Hartmann, T.N. & Greil, R. (2009) Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nature Reiews Clinical Oncology, 6, 405-418.
29. Ramsay, A.G., Johnson, A.J., Lee, A.M., Gorgun, G., Le Dieu, R., Blum, W., Byrd, J.C. & Gribben, J.G. (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. Journal of Clinical Investigation, 118, 2427-2437.
30. Ramsay, A.G., Clear, A.J., Fatah, R. & Gribben, J.G. (2012) Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood, 120, 1412-1421.
31. Schietinger, A. & Greenberg, P.D. (2014) Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends in Immunology, 35, 51-60.
32. Scrivener, S., Goddard, R.V., Kaminski, E.R. & Prentice, A.G. (2003) Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leukaemia & Lymphoma, 44, 383-389.
33. Shimatani, K., Nakashima, Y., Hattori, M., Hamazaki, Y. & Minato, N. (2009) PD-1 + memory phenotype CD4 + T cells expressing C/EBPalpha underlie T cell immunodepression in senescence and leukemia. Proceedings of the National Academy of Sciences of the United States of America, 106, 15807-15812.
34. Smith, P., Walsh, C.M., Mangan, N.E., Fallon, R.E., Sayers, J.R., McKenzie, A.N. & Fallon, P.G. (2004) Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages. The Journal of Immunology, 173, 1240-1248.
35. Tinhofer, I., Marschitz, I., Kos, M., Henn, T., Egle, A., Villunger, A. & Greil, R. (1998) Differential sensitivity of CD4 + and CD8 + T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood, 91, 4273-4281.
36. Wherry, E.J. (2011) T cell exhaustion. Nature Immunology, 12, 492-499.
37. Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., Segal, N.H., Ariyan, C.E., Gordon, R.A., Reed, K., Burke, M.M., Caldwell, A., Kronenberg, S.A., Agunwamba, B.U., Zhang, X., Lowy, I., Inzunza, H.D., Feely, W., Horak, C.E., Hong, Q., Korman, A.J., Wigginton, J.M., Gupta, A. & Sznol, M. (2013) Nivolumab plus ipilimumab in advanced melanoma. The New England Journal of Medicine, 369, 122-133.
38. Woo, S.R., Turnis, M.E., Goldberg, M.V., Bankoti, J., Selby, M., Nirschl, C.J., Bettini, M.L., Gravano, D.M., Vogel, P., Liu, C.L., Tangsombatvisit, S., Grosso, J.F., Netto, G., Smeltzer, M.P., Chaux, A., Utz, P.J., Workman, C.J., Pardoll, D.M., Korman, A.J., Drake, C.G. & Vignali, D.A. (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T cell function to promote tumoral immune escape. Cancer Research, 72, 917-927.
39. Workman, C.J., Cauley, L.S., Kim, I.J., Blackman, M.A., Woodland, D.L. & Vignali, D.A. (2004) Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. The Journal of Immunology, 172, 5450-5455.
40. Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D.M., Okumura, K., Azuma, M. & Yagita, H. (2002) Expression of programmed death 1 ligands by murine T cells and APC. The Journal of Immunology, 169, 5538-5545.